6-Month Lab Check on GLP-1: Markers to Watch
The 6-month mark is where the metabolic transformation becomes undeniable in your blood work.
At 6 months on GLP-1 medication, you have likely been at therapeutic dose for 2-4 months and lost 10-15% of body weight. Your blood work at this point typically shows dramatic improvements across nearly every metabolic marker.
Expected 6-Month Improvements
6-Month Lab Trends
| Marker | Typical Improvement |
|---|---|
| HbA1c | 0.5-1.5% decrease (prediabetes often resolves) |
| LDL cholesterol | 10-20% decrease |
| Triglycerides | 20-35% decrease |
| HDL cholesterol | 5-10% increase |
| CRP (inflammation) | 30-50% decrease |
| ALT/AST (liver) | Often normalize |
| Fasting insulin | 25-40% decrease |
| Blood pressure | 5-8 mmHg systolic decrease |
Recommended 6-Month Panel
- CMP, lipid panel, HbA1c (repeat core)
- TSH (thyroid recheck)
- CBC (blood count)
- Vitamin D, B12
- Nutrient panel if 30+ lbs lost
- Hormone panel if PCOS or testosterone concerns
- Liver function
Medication Reduction Conversation
By 6 months, many patients can discuss reducing diabetes medications (metformin, insulin), blood pressure medications, cholesterol medications (statins), and sleep apnea CPAP settings. Always work with your prescribing provider for safe medication adjustments.
See Your Numbers Improve
Trimi tracks your metabolic transformation with appropriate lab monitoring. Semaglutide $99/mo. Tirzepatide $125/mo.
Get StartedMedical Disclaimer
Lab improvements are typical ranges; individual results vary. Never adjust medications without physician guidance. Consult your healthcare provider.
More on GLP-1 lab monitoring
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).